Online Oncology Days | Day 1 - April 12, 2022 | 7 pm (CEST) / 1 pm (EDT)
Liver Cancer Imaging | CT/MRI/Post-Processing
Role of Imaging in Management of Liver Disease
The liver is a common site of metastatic spread, especially tumors from the colon, lung, pancreas and stomach, and in patients with chronic liver disease who are at risk for developing hepatocellular carcinoma. Both CT and MRI have a major role to play in all stages of this disease, from diagnosis, staging, treatment planning to follow-up. During this webinar, experts will guide you through all the possibilities in liver cancer imaging to maximize the image quality and enable clinicians to better treat this challenging disease.
This webinar occurs now in the past. The recording is available. Click here to watch it now.
The Current and Future Role of CT in Liver Cancer Imaging - Dr. Ewoud Smit
Liver Cancer Diagnosis with MRI - Dr. Benoit Sauer
CT Volumetry to Plan and Evaluate Percutaneous Treatment of HCC - Dr. Mark Burgmans
Why should you attend?
To be able to understand the latest advancements in CT imaging of the liver
Understanding the strengths and limitations of various MRI sequences for the liver
To understand how CT volumetry can help in treatment planning and evaluation points of hepatocellular carcinoma
INFORMATION ON SPEAKERS AND THEIR PRESENTATIONS
Moderator & Speaker: Dr. Ewoud Smit, MD, PhD
Radboud University Medical Center
Nijmegen, the Netherlands
Dr. Ewoud Smit is a radiologist at the Radboud University Medical Center with a great interest in Computed Tomography-related research. He received his medical degree from the University of Utrecht and his MSc. in Physics from the University of Groningen. He followed his residency at the University Medical Center in Utrecht, Meander Medisch Centrum in Amersfoort and Radboudumc in Nijmegen. He received his Ph.D. investigating the development of a single acquisition 4D-CT stroke protocol. In general, his research focuses on functional CT and dynamic CTA, in particular in stroke and body imaging. Currently, he is a consultant abdominal radiologist with a special interest in liver imaging.
Presentation Title: The Current and Future Role of CT in Liver Cancer Imaging
This presentation will touch on epidemiological data and the decision tree for liver cancer imaging. MRI is the most preferred imaging modality to diagnose liver cancer. However, there is an important role for CT in the imaging pathway for hepatocellular carcinomas, cholangiocarcinomas and metastases. CT liver cancer imaging may become even more essential, especially where there is the possibility to benefit from the latest CT advancements such as deep-learning reconstruction, subtraction CT, dual-energy. In the future, perfusion CT and multiple phase scans may be used to improve diagnostic confidence and aid treatment decisions.
Speaker: Dr. Benoît Sauer, MD
Medical Imaging Group - MIM, Clinique Sainte Anne
Dr. Benoît Sauer is a radiologist and is responsible for the imaging department in the Sainte-Anne clinic at Strasbourg. Particularly involved in oncology, he is implicated in the association Oncolia which federates almost all private oncologists, radiotherapists and surgeons of the region. He participates in multidisciplinary decision meetings in this field. His work is oriented towards collaboration with clinicians to optimize the treatment of patients suffering from cancer.
Presentation Title: Liver Cancer Diagnosis with MRI
MRI has become the gold standard for liver pathologies assessment. Without irradiation and sometimes without injection of contrast media, this modality allows differentiation between benign and malignant nodules and at the same time evaluation of surrounding organs. The optimization of sequences is the key point, especially in an altered condition such as with an elderly or fragile patient leading to achieving a better diagnosis and permitting appropriate personalized treatment. MRI is both used in the characterization of lesion and follow-up. Tips and tricks of MRI techniques should be considered to guide the clinicians or interventional radiologists in the choice and evaluation of treatments.
Speaker: Dr. Mark Burgmans, MD, PhD
Head of Interventional Radiology
Leiden University Medical Center
Leiden, the Netherlands
Dr. Mark Burgmans is a Dutch interventional radiologist at the Leiden University Medical Center and a staff member at the Technical University Delft. His field of expertise is interventional oncology, in particular thermal tumor ablation, transarterial chemoembolisation, radioembolisation, and percutaneous hepatic perfusion. Dr. Burgmans holds a PhD from the Leiden University (thesis ‘Advancements in minimally invasive image-guided liver therapies’) and is a principal investigator for studies on radiofrequency ablation with adjuvant Holmium radioembolisation, percutaneous hepatic perfusion with immunotherapy and quantitative ablation margin assessment using CT-CT co-registration. He is the current chairman of the Dutch Society of Interventional Radiology and board member of the Dutch Society for Hepatology.
Presentation Title: CT Volumetry to Plan and Evaluate Percutaneous Treatment of HCC
Hepatocellular carcinoma is the third most common cause of cancer related death. Interventional radiology provides minimally-invasive locoregional therapies at different stages of disease. CT volumetry provides valuable information that allows individualized treatment planning and evaluation. The lecture will discuss how CT volumetry can improve outcomes of percutaneous liver tumor treatment.
Scientific Evidence: Liver Cancer Imaging | MRI/CT/Post-processing
Download scientific evidence on oncology solutions using Canon technologies here.
P Hendriks et al. | Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software | J Oncol (2019)
Timo T M Oosterveer et al. | Study Protocol PROMETHEUS: Prospective Multicenter Study to Evaluate the Correlation Between Safety Margin and Local Recurrence After Thermal Ablation Using Image Co-registration in Patients with Hepatocellular Carcinoma | Cardiovasc Intervent Radiol. (2022)
The opinions expressed in this material are solely those of the presenter and not necessarily those of Canon Medical Systems. Canon Medical Systems does not guarantee the accuracy or reliability of the information provided herein.
The clinical results, performance and views described in this video/webinar are the experience of the clinician. Results may vary due to clinical setting, patient presentation and other factors. Many factors could cause the actual results and performance of canon Medical’s products to be materially different from any of the aforementioned.
Some products shown might not be available in all regulatory jurisdictions, please consult with your local Canon sales office for availability in your region.
Due to medical device regulatory reasons, not all products/services displayed on this Canon Medical Systems webpage are available in all countries or markets. Future availability of the products/service cannot also be guaranteed. Don't hesitate to contact your local Canon Medical Systems representative for further details.